Prospects of Disease-Modifying Osteoarthritis Drugs
Author:
- 8 April 2022
- journal article
- research article
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 38 (2) , 397-432
Abstract
No abstract availableKeywords
This publication has 123 references indexed in Scilit:
- MMP13 is a critical target gene during the progression of osteoarthritisArthritis Research & Therapy, 2013
- Teriparatide as a Chondroregenerative Therapy for Injury-Induced OsteoarthritisScience Translational Medicine, 2011
- Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosisNature Reviews Rheumatology, 2011
- Osteoarthritis subpopulations and implications for clinical trial designArthritis Research & Therapy, 2011
- Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trialsOsteoarthritis and Cartilage, 2010
- Identifying different osteoarthritis phenotypes through epidemiologyOsteoarthritis and Cartilage, 2010
- Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrixOsteoarthritis and Cartilage, 2009
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor SuppressorPLOS Biology, 2008
- Noninferiority and equivalence designs: Issues and implications for mental health researchJournal of Traumatic Stress, 2008
- Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled studyArthritis Research & Therapy, 2007